Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Rugo Relays the State of Immunotherapy in TNBC

The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.

Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.

Roswell Park's Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort

RET Inhibition Research: Next Steps

The Future of RET Inhibition in Clinical Practice

RET Inhibitors in Development

Effect of NGS Wait Time on Decision Making

Targeted Therapy Benefit for Actionable Mutations 

The Impact of Upfront NGS Testing on Overall Outcomes

The Importance of NGS Testing in NSCLC

Multikinase TKI Toxicity Profile

The Role of Multikinase TKIs for NSCLC

MOA and Rationale for RET Inhibitor Development

The Importance of Targeting RET in NSCLC

The Future of Treatment for Soft Tissue Diseases

GIST Treatment: Durability of Response and Challenges

Use of Targeted Therapy in GIST Mutations

Targeted Therapy Advancements in Sarcoma Subtypes

Immuno-Oncology

Immuno-Oncology | Specialty

Rugo Relays the State of Immunotherapy in TNBC

Rugo Relays the State of Immunotherapy in TNBC

Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China

Novel Combo Elicits Clinical Responses in Patients With "Cold" Melanomas

Roswell Park's Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort

RET Inhibition Research: Next Steps

The Future of RET Inhibition in Clinical Practice

RET Inhibitors in Development

Effect of NGS Wait Time on Decision Making

Targeted Therapy Benefit for Actionable Mutations

The Impact of Upfront NGS Testing on Overall Outcomes

The Importance of NGS Testing in NSCLC

Multikinase TKI Toxicity Profile

The Role of Multikinase TKIs for NSCLC

MOA and Rationale for RET Inhibitor Development

The Importance of Targeting RET in NSCLC

The Future of Treatment for Soft Tissue Diseases

GIST Treatment: Durability of Response and Challenges

Use of Targeted Therapy in GIST Mutations

Targeted Therapy Advancements in Sarcoma Subtypes